This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk13: And ladies and gentlemen, thank you for standing by and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question and answer session. The advice at today's conference call may be recorded. I would now like to hand the conference over to Tiffany Aldrich, Senior Manager, Corporate Communications at Experian. Please go ahead, Tiffany.
spk10: Thank you, Carmen. Good morning, and welcome to Asperion's second quarter 2022 financial results and company update conference call. I'm Tiffany Aldrich, and I'm part of the corporate communications team here at Asperion. I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's press release and our SEC filings. The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast August 2, 2022. We undertake no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast. As a reminder, this conference call and webcast are being recorded and archived. We issued a press release this morning detailing the contents of today's call. A copy can be found at www.esperion.com within the Investors and Media section. We will begin with prepared comments and then open the call for your questions. Following today's call, the team will be available for follow-up questions. Please email corporateteam at esperion.com to schedule time to speak with the team. With us today are Sheldon Koenig, President and CEO, Dr. Joanne Foody, Chief Medical Officer, Eric Warren, Chief Commercial Officer, BJ Swartz, Chief Strategy Officer, and Ben Halliday from our Finance Department. I'll now turn the call over to Sheldon for some prepared remarks. Sheldon?
spk03: Thank you, Tiffany, and good morning, everyone. It's incredibly exciting to speak to you today about our significant progress in the second quarter of this transformational year for Aspirion and highlight our remaining areas of focus for 2022. We are pleased to announce that while continuing to drive consistent growth, We have achieved 100% MACE IV accumulation in our unprecedented Clear Outcomes trial and are rapidly approaching the most significant inflection point for the organization to date. We remain on schedule to report top line results for Clear Outcomes in early first quarter 2023. We continue to execute quality site closeout visits, scrub the database, and ensure accurate and complete data collection and database lock from this large global trial encompassing 1,200 study sites and over 14,000 patients. We plan on releasing a brief top line statement of primary endpoint results early in the first quarter, with comprehensive study results to be presented at a major medical conference in the latter part of the quarter. The upcoming clear outcomes readout represents a significant catalyst for our business and for patients as a positive outcome study and the ensuing label has the potential to make benpidoic acid the only oral LDL lowering therapy since statins to be indicated for CV risk reduction. The entire organization is working in unison to ensure flawless reporting and launch of these data and to deliver on our commitment to driving exponential growth for both NexLatal and NexLisette. A large 300 healthcare provider payer market research project conducted in Q2 validated that positive data would unlock exponential growth through improved market access and expanded market share. At the same time, we have assembled a diverse and prominent group of scientific experts for our Scientific Advisory Board and are preparing to share with you our longer-term plans for our innovative pipeline at our R&D Day in November. Our partner, Daiichi Sankyo, reported strong Nalemdo and Newstendi growth in their European territory and have cumulatively treated at least 70,900 patients. The previously launched markets include Germany, UK, Luxembourg, Austria, and Belgium. Switzerland was launched with reimbursement in second quarter of 2022, and Spain was launched during the second quarter of 2022 for private market sales. Additionally, our partner Otsuka now has results from its phase two dose finding trial of benpidoic acid and plans to advance the program into phase three. I am also pleased to report that this quarter we continue to achieve year over year cost savings of $9.4 million in our operational expenses compared to the second quarter of 2021 as we pull forward our transformative plan announced in the fall and continue to focus on efficiently allocating our resources in advance of the top line readout of the clear outcomes trial. In the first half of 2022, we have spent $47 million less in operating cash compared to the first half of 2021. Earlier today, we issued a press release containing our financial results for the second quarter, which is available on our investor website. U.S. product revenue for the second quarter ended June 30, 2022, was $13.6 million, up 28% year-over-year. and $26.9 million for the six months ended June 30, 2022, up 59% year-over-year. Royalty revenue for the second quarter ended June 30, 2022, was $1.5 million, up 50% year-over-year, and $2.6 million for the six months ended June 30, 2022, up 63% year-over-year, driven by new country launches and continued growth in previously launched territories. We expect our partner to continue launching the LEMDO and NISTENDY to new geographies. Combined royalty and partner revenue was $5.3 million for the second quarter ended June 30th, 2022, a decrease of 82% year over year, and $10.7 million for six months ended June 30th, 2022, a decrease of 66% year-over-year attributed to a large milestone payment of $28.1 million that was booked to revenue in second quarter 2021. When adjusting for this one-time payment, total partner revenue grew 170% in the second quarter ended June 30th, 2022. Finally, total revenue for the second quarter ended June 30th, 2022 was $18.8 million compared to $40.7 million for the second quarter of 2021, an increase of approximately 50% year over year after adjusting for the one-time upfront payment. Turning to expenses, gross margin decreased as a percentage of revenue, largely driven by an increase in the purchase of inventory from our international partners, which has a lower margin than our US sales. We expect this margin to improve over the year as shipments reach a steady state compared to the first half of 2022. R&D expenses for the second quarter ended June 30, 2022, were $32.4 million, an increase of 29% year-over-year, and $56.8 million for the six months ended June 30, 2022, an increase of 7% year-over-year. The increases were primarily driven by the acceleration of expenses related to the rapid closeout of the clear outcome study earlier in the year. SG&A expenses were $29.6 million for the second quarter ended June 30th, 2022, a decrease of 36% year over year, and $60 million for the six months ended June 30th, 2022, a decrease of 44% year over year. These decreases reflect savings from the transformation for long-term success plan implemented Q4 of 2021. As of June 30, 2022, cash, cash equivalents, restricted cash, and investment securities available for sale total $235.8 million, compared with $309.3 million on December 31, 2021. We are well capitalized even without our $50 million of restricted cash and anticipate that our cash runway extends through the anticipated completion and readout of the Clear Outcomes Trial and continues to fund continuing operations for the foreseeable future following those results. Our operating expense guidance for the full year 2022 remains unchanged. We continue to anticipate full-year 2022 R&D expenses to be between $100 to $110 million and SG&A expenses to be between $120 to $130 million. These estimates are inclusive of approximately $25 million of non-cash stock-based compensation expense expected to be incurred during this year. To close, I want to highlight that we are approaching a significant catalyst in our Nexlatol story with the potential to harvest over $1 billion in partner milestones and significantly higher revenues until patent expiry in mid-2031 with a positive readout of our clear outcomes trial. We believe we are part of a paradigm shift in the management of lipids as LDL cholesterol is the foundation of cardiovascular risk reduction. Early upfront combination therapy is an approach for most chronic diseases, including hypertension and diabetes. Our products have the potential opportunity to address LDL cholesterol with early combination therapy in much the same way. Therefore, we are poised to begin an entirely new chapter for our company with opportunities to help even more patients reach their goals. We look forward to updating you on our progress as we near a crucial milestone in our journey to help patients address the leading cause of death worldwide. Thank you all for joining today and for your continued support and interest in Aspirion. Operator, we are now ready for Q&A.
spk13: Thank you. And as a reminder, to ask a question, simply press star 11 on your telephone. One moment while we compile the Q&A roster. Our first question comes from Michael Yee with Jefferies. Please go ahead. Michael, your line is open. Please check your mute button, Mr. Yee.
spk03: We're ready, Mike.
spk12: We just need to hear you.
spk13: Can I continue with the next question? Maybe he can't hear you.
spk03: Yeah, as long as we can come back to Mike, that would be great.
spk13: No problem. One moment for our next question. We have a question from Joseph Tomei with Cowan. Please go ahead.
spk05: Hi there, good morning, and thank you for taking my question. Maybe just as you're thinking about a potential sales inflection, I know you mentioned doing some work in the second quarter. Is there a level of CV risk reduction that you think physicians are looking for in order to use the therapy a little bit more in their patients, or is just kind of, you know, seeing if that's a benefit in the outcomes trial going to be sufficient? Are they looking for anything more, or are they giving you any kind of numbers to set guidelines?
spk03: Yeah. Hey, Joe. First of all, good morning, and thank you for the question. So I think it's a little bit of both. I think it is the outcomes and waiting for outcomes. And also, they are looking for, you know, a certain result, you know, something obviously that is positive. You know, I think there's always also two levels. There's an academic level, and then there's the, if you will, for lack of better words, common prescriber. From an academic perspective, when the study reads out, you know, this study is powered for a 15% residual risk reduction, and I do think that from an academic perspective and discussion, physicians will be talking about that, will be speaking to different metrics, the statistical significance, maybe even looking at subgroups, etc., payers and physicians are looking for outcomes. But with that in mind, we also did, as I mentioned in my previous remarks, we just conducted a very large quantitative market research to examine this, and I'll have our chief commercial officer add some color to that.
spk15: Sure. Thanks, Sheldon. Thanks for your question, Joseph. Yeah, so the level of reduction, we looked at multiple flavors in this 300 HCP and payer quant study. And we found that at that 15% level of reduction, which is the base, which is what the study is powered for, we experienced that significant inflection. We also looked at different flavors of potential outcome. So I'm really encouraged by the results we saw from that study. And again, at the base level of impact, if you will, the 15% that the study is powered for, we see that significant value.
spk05: Perfect. And maybe just some more if I can. Obviously, that's going to be the key inflection driver here. Before then, though, when you're discussing with your physicians and the sales teams are out there, is there anything you can do in the interim? Are the physicians really just saying we need outcomes and obviously the payer structure to change a little bit? Or are they able to get the therapy? Is there anything else that you can kind of try and unlock to grow scripts in the more near term and even beyond, I guess, the new data?
spk15: Yeah, so Joseph, it's Eric again. So as you know, in October of 21, we made the conscious decision to scale back some of our commercial footprint and investment in anticipation of the future clear outcomes. And the fact that really that's going to create the most bang for our buck. I will say, though, that in our current structure and footprint, we've been able to consistently deliver this growth and 6% volume growth this quarter. Prior authorizations continue to be a bit of a challenge for HCPs. We've implemented a program in the middle of last year to help solve that. We've really amped up our resources associated with that program. We've deployed, actually, individuals from LabCorp just recently to help HCPs navigate the prior authorization environment a little bit closer. And clear outcomes really is the catalyst for breaking the prior authorization barrier, if you will. The burden of prior authorizations is real now, but with the clear outcomes data, we expect a very significant reduction in that difficulty or that barrier associated with PAs.
spk05: Perfect. Very helpful. Thank you very much.
spk03: Welcome. Operator, can we try Mike again to see if he's able to ask a question?
spk13: Mr. Yee, if you can press star 1 1 on your telephone keypad.
spk12: OK.
spk03: Having some type of technical issue. Yes.
spk13: I do not see him, sir.
spk03: OK.
spk13: One moment for our next question, please. Our next question comes from Mr. Jeff Hong with Morgan Stanley. Please go ahead.
spk01: Hi, this is Mike Riad on for Jeff Hong. Can you provide us any updates on the engagement process with HCPs? Are you hearing more patients returning to physician offices, or has that stabilized at all? Eric, do you want to?
spk15: Yeah, good morning, and thanks for your question. So the environment is returning to quote-unquote more normal. Still challenging from a cardiovascular perspective in that there is a lot of unmet need, but there's also apathy that needs to be addressed in the marketplace. So patients are returning to the office. Our HCPs are able to interact. with our sales representatives more and more, but there still is apathy in the market that does need to be addressed.
spk01: Perfect. And maybe just a quick follow-up, if I could. For the program that you had mentioned, I think it's like the Next Step program on increasing adherence. What do you see as the main drivers for this program to actually be able to increase adherence, and what are you looking for out of this?
spk09: I'll take that question. It's BJ's words. As far as the Next Step Navigator program, what we see is physicians still, even though we have a 90% commercial coverage and significant Medicare coverage, the prior authorization burden has been such not allowing patients to get the product in the shortest period of time. So the biggest driver is really assisting with the prior authorization to ensure patients do get their product when the physician puts the pen to the pad in the shortest period of time. We had just, as Eric mentioned, partnered with LabCorp for a program to have field reimbursement support in the field. And that group will work hand in glove with the offices and payers to stay on those prescriptions until the patient gets the prescription in hand. And so we are super excited about that program that just kicked off July 1st.
spk01: Awesome. Thank you so much, and congrats again on reaching 100% accumulation.
spk03: Thank you. Thank you.
spk01: Thank you. One moment for our next question, please.
spk12: All right, we have the line of Mr. Michael Yee with the Jefferies open.
spk13: Please go ahead.
spk02: Good morning. Can you hear me? Yes, great. Hey, Mike.
spk01: Sorry about that.
spk02: I like going back to the Zooms. Two questions, one on the commercial and then one on the thinking about the outcome study. On the commercial, I know it grew 5.9%. Just wondering if there were any changes to gross to net or inventory in the quarter, the reported number was actually a little bit lower than that amount. So just trying to figure out quarter to quarter what was going on there, are there any changes?
spk16: And then on thinking about when the outcome study reads out in early first quarter, I know you have historically said that it will take some time to get the label and traction to market all of that. So that will take some time. And I know that there are different avenues of capital to seek. Can you just remind us, I think one is the warrant coverage that's out there. Remind me that's one, but just talk to us about how you would foresee the different scenarios for capital post the outcomes. Thanks.
spk03: Sure. Will do. So first of all, I'm glad we could get your line unmuted there, Mike. And again, apologize for any of the technical difficulties. Regarding your question as it relates to growth to net, We had two things that occurred in the quarter. One was we actually initiated a contract of Medicare coverage. It was a win at Cigna, and we started to see the volume come through with that contract. We also had Medicare coverage gap that we also had to pay during the quarter. The Cigna win we view as a win for us, not only for the quarter, but in the future. You know, today, you know, when we announced the fact that we have the 100% MACE4 accumulation, that's one big step forward, again, to what we've been consistently describing as the clear outcome study being an inflection point for us. So we're, you know, one step closer to that. I bring that up because that's going to allow for us to have more volume of prescribing once the clear study actually reads out. And that's what's really going to help stabilize our GTN. And I would move forward to say that volume increases also will significantly reduce our distribution fees as well. So, you know, we're well poised as it relates to moving forward. having the clear outcome study, and again, that will be our inflection point for volume and allow us to stabilize our growth to net. But these events that occurred, Medicare coverage gap and also the win at Sigma, at Cigna, sorry, is really like any other pharmaceutical business, and this is the cost of doing business, and we were happy to see the consistent growth in volume, as you mentioned, of 5.9%, and we've been consistent in saying that, that we would demonstrate continuous growth through the year. As it relates to capital strategy and the warrant coverage, et cetera, so we did do the raise of last December, and that did come with warrants, at a strike price of $9. If you look at the total value of those warrants, they're roughly $305 million. They have a two-year expiry on them. And our capital strategy, although we're not giving explicit details, once we have the clear outcome study in hand, We believe that we have a lot of different pathways that we can go as it relates to getting the capital that we need in order to move forward. As I mentioned in our prepared remarks, we're well capitalized to the end of the clear outcome study and some runway post the study, but we will be looking at what levers do we want to use as it relates to bringing in capital once we have our positive clear outcome study.
spk16: Okay, thanks, guys.
spk13: Thank you. One moment for our next question, please. Our next question comes from Jessica Tsai with JP Morgan. Please go ahead. Hey, guys. Good morning.
spk14: Thanks for taking my questions. First one is... Good morning. Following up on the comments about your market research, What does your market research suggest about the potential change in utilization of Nexatol and Nexazet once the outcomes data are available? Second, can you walk us through how you think about the magnitude of event reduction in clear outcomes based on the LDL baseline, the patients enrolled, and the expected LDL reduction you can achieve in this population? And third, following up on Mike's question, do you expect... make meaningful changes in net price once your outcomes data is available, you know, beyond just maybe economies of scale on distribution? On the one hand, it seems like it's sort of hard to move that net price higher, even irrespective of new data. But any indication from the payers there? Or is it less about improving that price and more about volume? Thanks.
spk15: Absolutely. Eric, you want to start? Great. Yeah, good morning, Jess. So with regards to the market research study, we saw, and I'll just categorize them as exponential increases in penetration from the HCPs that we interviewed and that ultimately participated in the quant. And per the other question that came in earlier, these exponential increases in penetration came at that base level of benefit or that 15% which the study is powered for. We also saw improvements, significant improvements from a payer perspective in both the breadth of coverage as well as improvements in the utilization management criteria that will make it much easier for HCPs to prescribe the product.
spk11: Jess, this is Joanne. Thank you so much for your question. I think we are absolutely thrilled that we've hit 100% MACE4 accumulation for the CVOT and are really looking forward to our top-line results, Q1 of 2023. To your question regarding, I'll say, reasons to believe and confidence in the study, the study, as you know, is powered for a 15% reduction in cardiovascular events. based on all that we know about benpidoic acid. I think, though, as we think about this, understand that the population is very unique. It has the highest LDL cholesterol of any recent non-statin trial, that being 139 milligrams per deciliter. And not only is the LDL high, but it's a very unique population with 80% of patients not able to take a statin. We know that in patients like these, as well as given the high rates of diabetes, prediabetes, and obesity in the cardiovascular outcome trial, that these patients tend to be hyper-responders to our drugs. If we look further at a SMART analysis conducted by Kosh Ray and now published, we see a potential cardiovascular risk reduction closer to 20%. So we are highly confident in this study, again, emphasizing that it's powered at 15%. As Eric previously mentioned, that is enough to move the needle in the clinical community. And we look forward to having, hopefully, positive results and having benpidoic acid be the first non-statin oral therapy with cardiovascular risk reduction outcomes and a potential label as we move forward.
spk03: Great. Thanks, Joanne. And then, Jess, for your question regarding net price and how we can demonstrate meaningful improvement beyond just economies of scale, I'll have BJ answer that, who's actively working on that. BJ?
spk09: Thank you, Jeff. As Sheldon mentioned, the wholesaler DSA fees, if that volume is unlocked, those fees will be reduced. But also, as the volumes increase with our payer contracts that are in place and we hit a break-even from a profitability standpoint, and then hit the trajectory of growth, that's another significant factor in reducing the GTN. We recently just had a payer advisory board in person and actually conducted a mock P&T. And at that mock P&T, the payers all agreed that significant volume will be unlocked with the readout of CLEAR. And so we're very excited about that. Again, in the interim, as mentioned, we partner with LabCorp for the field reimbursement support team that will work hand in glove now And also payers are starting to re-look at their UM criteria even prior to the clear outcomes readout based on the demand that we start to see of patients with payers.
spk03: I would just add, we've also just have recently seen in the past week or so, we've talked about this before, but we have Aspen, which is somewhat of a mini hub for us that actually helps physicians facilitate prior authorization fulfillment as physicians offices and for patients so they can get the drug. And we've seen the highest increase ever in this program. We had actually over 300 patients in one week alone. So this is again something very promising and we're starting to really see this as we move forward and also awareness grows.
spk13: Thank you. Thank you. One moment for our next question please. Our next question comes from Judah Frommer with Credit Suisse. Please proceed.
spk07: Thanks for taking the question, guys. Good morning. Could you just remind us of the timing around potential guideline changes and then potential label change? And then you did call out in the release the UT Southwestern real-world data that you collected. It does seem like there's going to be another lift in terms of ensuring To new guidelines, how do you plan on on tackling that?
spk11: So, Judah, thank you so much. So, so, as we mentioned, right, we will anticipate our data from the to be available publicly. Uh, Q, 1 of 2023. With those data, we anticipate then the potential for guidelines to be updated, whether it be from the American College of Cardiology, the American Heart Association, or the European Society of Cardiology within 2023. As then, we would anticipate label being filed and submitted as quickly as possible thereafter with an anticipated label in first half of 2024. Understand, though, that many of the patients within the cardiovascular outcome trial are on label for us currently in the US, and we imagine that that will cause an increased utilization of the product, then bolstered by guidelines, which then will also improve or reduce prior authorizations potentially as we move forward. So we see this as really a critical inflection for the organization, for providers, and for patients as we get this therapy out to them.
spk07: Okay. Is, I guess, another way of asking the question, is updating the guideline, you know, enough to reduce prior authorization burden, and do you think that's enough to increase utilization, or do you, you know, have the Salesforce go out and alert providers to guidelines as well?
spk11: So, Judah, first, I think that having the study in public domain is enough, irrespective of the guidelines, to change payer conversations. And BJ can speak more to that and to our strategy to engage payers prior to the guidelines.
spk09: Yes. So, certainly, the readout is going to be helpful, but with the guidelines, Payers always look to other resources. In the meantime, they also look to validate with large societies and all of the associations. So again, I think from our recent payer advisory board that we just had, the mock P&T, that was one area that the advisors told us as well, as soon as they saw the guidelines, that that would be tremendous in validating the utilization and validating changing their prior authorizations and UM criteria.
spk13: Great, thank you. One moment for our next question, please. Our next question comes from Serge Belanger with Needham & Company. Your line is open.
spk06: Hi, Serge. Hi, good morning. Just a couple questions on the ongoing European launch. It looks like the product will be available in all the major markets by the time the outcome study reads out. Just curious if you expect the same kind of inflection in improved access and expanding market share with a positive outcome study in Europe as you do in the US.
spk03: Sure. So you are correct that most of the major markets either have launched or will be launched. In Europe, Daiichi Sankyo has been very successful. As a matter of fact, in the US, we actually look at their launch as almost a marker for us when we have our outcome study. And the reason why I say that is because when you do a comparison of the EU label to the US label, One of the biggest headwinds for us in the U.S. is the fact that patients have to be on the maximum tolerated dose of a statin, and they also have to be identified as having ASCVD, which is in Europe, they do not have that hurdle. Upon the CLEAR label here in the U.S., those elements, maximum tolerated dose of a statin, having to actually identify a patient as ASCVD, those will go away, and those will reduce the hurdles of patients as it relates to getting the drug here in the United States. Now, in Europe, just getting back to your question, we actually think that, again, based upon the success that they already have, having the outcome study and having residual risk reduction and looking at other cardiovascular products that have launched that have outcomes in Europe, you always see an inflection post-outcome as it relates to more uptake, especially if you can show a reduction of risk. And as Joanne mentioned in a previous question, this is a very unique study, as you know, Serge. It's not only the fact that we're looking at an LDL level of 139 milligrams per deciliter, but there's also areas that we're looking at from a perspective of HSCRP, glucose, and a median follow-up time of close to four years, which is dramatically different than other lipid-lowering products that demonstrate outcomes, whether that be in Europe or the U.S. So this will definitely help our partners in Daiichi, thank you, continue to fuel their success.
spk12: Does that answer your question, Serge? It does. Thank you.
spk13: Thank you. One moment for our next question. Our next question comes from Jason Butler with JMP Securities. Please proceed.
spk08: Hi. Thanks for taking the question. When you established the Scientific Advisory Board, you noted the potential for lifecycle management. Obviously, I understand that you're fully focused on clear outcomes right now, but can you just talk to the longer opportunities that you might be able to evaluate with lifecycle management of the franchise?
spk03: Yes, we can. Sorry, Jason. We were moving our phone here. But, yeah, first of all, we're really excited about the fact that we have the scientific advisory board and the people that are in our scientific advisory boards. We will be having an R&D day that's going to take place. We mentioned in November. We haven't given the specific date yet. But, you know, here at Aspirion, we do have a very interesting pipeline. We have never really talked about it before. We have a second-generation ACL. We also have an oral PCSK9. But I'll have Joanne maybe just highlight some of the things that, you know, we'll be thinking of as we move forward with the SAB. Okay.
spk11: Yeah, thank you so much. We, again, are thrilled to have a scientific advisory board that has a deep and experienced expertise with really internationally renowned researchers, including Dr. Peter Libby as our co-chair of the scientific advisory board. We felt this was critical to set this up to really ensure that we had the best direction for our assets in our pipeline. the first being the platform for our ATP citrate life inhibitor, if you will, the next generation of benpidoic acid, and leveraging all their scientific expertise to bring in the best technologies, approaches to ensure the maximal value being brought to that pipeline set of assets. And just to be clear, the next generation has opportunities not only in cardiovascular, but in broad cardiometabolic features such as NASH, kidney disease, and even broad-reaching implications in oncology. And our advisors reflect that with a broad and diverse range. We also have our oral PCSK9 inhibitor, again, moving forward in preclinical phases. So, again, stay tuned for Research and Development Day in November, where we'll have an opportunity to focus on that, as well as once we have the top-line information from clear outcomes, the opportunity to think more deeply about life cycle management as we move forward with benpidoic acid.
spk08: Great. Thanks for taking the question. You're welcome. Thanks, Jason.
spk13: Thank you. One moment for our next question. And our next question is from Paul Choi with Goldman Sachs. Please proceed.
spk04: Good morning and congratulations on achieving the 100% of your MACE IV events in your study. A few questions from us, please. Have you scheduled any payer discussions just for early 2023 post your top line data just for improving access and working on the prior authorization barriers that you referenced earlier? Are these meetings already scheduled or will you have to schedule them after the top line data?
spk09: Paul, it's BJ. Thank you for your question. We absolutely are having those meetings are scheduling now, but we are in constant engagement with our payers, just improving the UM criteria prior to that as well. So we have our payer value proposition deck ready to go, and we're super excited, and as are the payers for the readout. So they will be taking place, and part of what the payer team can do, coupled with medical, is we can actually engage in some of this succession way before the label change or anything there. And so those discussions we're getting excited for, as are the payers as well. As evidenced by Cigna just adding us to formulary, they're certainly seeing the demand, and so we're excited for the future.
spk04: Okay, great. Thanks for that. And then I know you'll probably detail this a little bit more at your upcoming R&D day, but with the operating expense, I guess, around clear outcomes starting to wind down here in the back half of this year. Can you maybe just speak to, you know, how you're thinking about the cadence of potential INDs for those assets that you were describing earlier, Joanne, like the oral PCSK9 and your next generation ACL compound as a follow-up to bempedoic acid? Should we expect INDs to start trickling out in 23, or are you assuming sort of longer timelines there?
spk11: So, Paul, thank you so much. I think as we think about it, trickle out is the right word. Probably the very earliest we would think would be the end of 2023, depending on the approach. A lot of that is hinged, too, on where we stand after the outcome study with respect to benpidoic acid and potential opportunities there. but as well with the next generation platform in oral PCSK9. More likely, the rollout, as we look at prioritizing indications across the platform for ACLI, would be more likely the bulk of those in 2024. Oral PCSK9, again, similarly, it would anticipate probably 2024 as we think about that.
spk04: Okay, great. Thanks for taking our questions.
spk05: Thanks, Paul.
spk13: Thank you. And as a reminder, ladies and gentlemen, if you have a question, simply press star, then 1-1 on your telephone keypad. And I'm not showing it. And as a reminder, ladies and gentlemen, if you have a question, simply press star, then 1-1 on your telephone keypad. And I'm not showing any further questions in the queue, sir.
spk03: Great. I just want to, first of all, for those on the line, again, thank you for your interest and your questions. The organization is extremely excited about what we've announced today of getting one step closer to realizing the clear outcomes trial with the fact that we've accumulated 100% of the MACE IV accumulation. So thank you all again, and have a great day.
spk13: And thank you, ladies and gentlemen. This concludes today's conference call. Thank you for participating, and you may now disconnect.
spk10: The conference will begin shortly. To raise your hand during Q&A, you can dial star 11.
Disclaimer